BR112014023530A2 - diagnóstico farmacêutico - Google Patents

diagnóstico farmacêutico

Info

Publication number
BR112014023530A2
BR112014023530A2 BR112014023530A BR112014023530A BR112014023530A2 BR 112014023530 A2 BR112014023530 A2 BR 112014023530A2 BR 112014023530 A BR112014023530 A BR 112014023530A BR 112014023530 A BR112014023530 A BR 112014023530A BR 112014023530 A2 BR112014023530 A2 BR 112014023530A2
Authority
BR
Brazil
Prior art keywords
diagnosis
pharmaceutical
pharmaceutical diagnosis
pi3k
kits
Prior art date
Application number
BR112014023530A
Other languages
English (en)
Inventor
Fritsch Christine
Furet Pascal
Maira Sauveur-Michel
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48083130&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112014023530(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR112014023530A2 publication Critical patent/BR112014023530A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

resumo patente de invenção: "diagnóstico farmacêutico". a presente invenção refere-se, em parte, a novas terapias personalizadas, kits, formas transmissíveis de informação, e métodos para uso em regimes de tratamento seletivo de câncer com base em ensaio para a presença ou ausência de uma mutação em um ácido nucleico que codifica glutamina na posição 859 da subunidade catalítica p110a de pi3k.
BR112014023530A 2012-03-29 2013-03-27 diagnóstico farmacêutico BR112014023530A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261617284P 2012-03-29 2012-03-29
US201361767848P 2013-02-22 2013-02-22
PCT/EP2013/056600 WO2013144249A1 (en) 2012-03-29 2013-03-27 Pharmaceutical diagnostic

Publications (1)

Publication Number Publication Date
BR112014023530A2 true BR112014023530A2 (pt) 2017-07-18

Family

ID=48083130

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014023530A BR112014023530A2 (pt) 2012-03-29 2013-03-27 diagnóstico farmacêutico

Country Status (25)

Country Link
US (1) US9795596B2 (pt)
EP (1) EP2830621B1 (pt)
JP (1) JP6224067B2 (pt)
KR (1) KR20140138771A (pt)
CN (1) CN104271136A (pt)
AR (1) AR090544A1 (pt)
AU (1) AU2013241752B2 (pt)
BR (1) BR112014023530A2 (pt)
CA (1) CA2866127A1 (pt)
CL (1) CL2014002576A1 (pt)
CO (1) CO7091176A2 (pt)
EA (1) EA028984B1 (pt)
EC (1) ECSP14025016A (pt)
ES (1) ES2845560T3 (pt)
GT (1) GT201400206A (pt)
HK (1) HK1200723A1 (pt)
IL (1) IL234658B (pt)
IN (1) IN2014DN08970A (pt)
MX (1) MX2014011682A (pt)
NZ (1) NZ628596A (pt)
PH (1) PH12014502168A1 (pt)
SG (2) SG11201405169SA (pt)
TW (1) TW201345525A (pt)
WO (1) WO2013144249A1 (pt)
ZA (1) ZA201405938B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014229240B2 (en) * 2013-03-15 2017-06-15 Novartis Ag Biomarkers of tumor pharmacodynamic response
WO2015172085A2 (en) * 2014-05-09 2015-11-12 Memorial Sloan-Kettering Cancer Center Biomarkers for response to pi3k inhibitors
RU2690685C2 (ru) * 2014-10-03 2019-06-05 Новартис Аг Фармацевтические композиции, содержащие алпелисиб
CN108366998A (zh) * 2015-12-03 2018-08-03 诺华股份有限公司 在ctdna中具有pik3ca突变的预选患者中用pi3k抑制剂治疗癌症
WO2019199860A1 (en) * 2018-04-09 2019-10-17 The Research Foundation For The State University Of New York Genetically modified t-cells and pi3k/akt inhibitors for cancer treatment

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
DE68908054T2 (de) 1988-01-21 1994-03-10 Genentech Inc Verstärkung und nachweis von nukleinsäuresequenzen.
CA1340807C (en) 1988-02-24 1999-11-02 Lawrence T. Malek Nucleic acid amplification process
US5130238A (en) 1988-06-24 1992-07-14 Cangene Corporation Enhanced nucleic acid amplification process
EP0425563B1 (en) 1988-07-20 1996-05-15 David Segev Process for amplifying and detecting nucleic acid sequences
US5169766A (en) 1991-06-14 1992-12-08 Life Technologies, Inc. Amplification of nucleic acid molecules
US5846717A (en) 1996-01-24 1998-12-08 Third Wave Technologies, Inc. Detection of nucleic acid sequences by invader-directed cleavage
US5605798A (en) 1993-01-07 1997-02-25 Sequenom, Inc. DNA diagnostic based on mass spectrometry
GB2453173A (en) 2007-09-28 2009-04-01 Dxs Ltd Polynucleotide primers
CA2730271A1 (en) 2008-07-07 2010-01-14 Xcovery Holding Company Llc Pi3k isoform selective inhibitors
UA104147C2 (uk) * 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
CN101445832B (zh) * 2008-12-23 2011-09-14 广州益善生物技术有限公司 Pik3ca基因突变的检测探针、液相芯片及其检测方法
AR082418A1 (es) * 2010-08-02 2012-12-05 Novartis Ag Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico

Also Published As

Publication number Publication date
CN104271136A (zh) 2015-01-07
ECSP14025016A (es) 2015-09-30
IL234658B (en) 2018-02-28
JP2015514080A (ja) 2015-05-18
SG11201405169SA (en) 2014-10-30
EP2830621B1 (en) 2020-10-21
ZA201405938B (en) 2015-11-25
SG10201608001RA (en) 2016-11-29
PH12014502168A1 (en) 2014-12-10
TW201345525A (zh) 2013-11-16
US9795596B2 (en) 2017-10-24
CO7091176A2 (es) 2014-10-21
AU2013241752B2 (en) 2016-07-07
GT201400206A (es) 2017-09-28
NZ628596A (en) 2015-10-30
JP6224067B2 (ja) 2017-11-01
ES2845560T3 (es) 2021-07-27
IN2014DN08970A (pt) 2015-05-22
MX2014011682A (es) 2015-01-22
AU2013241752A1 (en) 2014-09-25
HK1200723A1 (en) 2015-08-14
CA2866127A1 (en) 2013-10-03
EA201491787A1 (ru) 2015-01-30
CL2014002576A1 (es) 2015-01-23
EA028984B1 (ru) 2018-01-31
US20150111927A1 (en) 2015-04-23
AR090544A1 (es) 2014-11-19
WO2013144249A1 (en) 2013-10-03
EP2830621A1 (en) 2015-02-04
KR20140138771A (ko) 2014-12-04

Similar Documents

Publication Publication Date Title
BR112015011171A2 (pt) compostos de pirrolopirimidina como inibidores da quinase
BR112014023530A2 (pt) diagnóstico farmacêutico
BR112014027128A2 (pt) antígenos associados à próstata e regimes de imunoterapia baseada em vacina
CO7350624A2 (es) Inhibidores de la tirosina-quinasa de bruton
GT201500249A (es) Terapia de combinación
BR112015010072A2 (pt) imizado[1,2-a]piridinacarboxamidas substituídas com amino e sua utilização
BR112012017150A2 (pt) formulação de anticorpo e regimes terapêuticos.
BR112013033943A2 (pt) sistema para uso com uma ou mais fontes de dados filiados de paciente, métodos para atualizar um conjunto de dados de orientação específico de paciente, atualizar uma pluralidade de bancos de dados de dispositivos de interface de paciente, operar um dispositivo de interface de paciente, administrar dados em um sistema, e, dispositivo de interface de paciente
BR112014031310A2 (pt) anticorpos anti-pcsk9, formulações, dosagem e métodos de uso
BR112015025711A2 (pt) terapia de combinação com ibrutinibe
BR112015012644A2 (pt) método para determinar a necessidade de um paciente com câncer, método de tratamento do câncer, composição farmacêutica, uso de um ácido nucleico ou anticorpo e kit;
BR112015005227A2 (pt) inibidores de glicosilceramida sintase
BR112016001114A2 (pt) membros da família tnf direcionados modificados
BR112013002250A2 (pt) composto, medicamento, método para a profilaxia ou tratamento de depressão, esquisofrenia, mal de alzheimer ou distúrbio de hiperatividade e déficit de atenção, e, uso de um composto.
BR112013010574A2 (pt) anticorpo, fragmento funcional do anticorpo, composição farmacêutica, usos de um anticorpo ou um fragmento funcional do mesmo e de pelo menos um membro selecionado do grupo que consiste de paclitaxel, carvoplatina, cpt-11, vinblastina, e 5-fu, polinucleotídeo, vetor, célula hospedeira transformada, e, método de produzir o anticorpo
BR112014015851A2 (pt) proteínas de ligação específicas duplas direcionadas contra il-13 e/ou il-17
BR112016008477A2 (pt) Corpos, ácido nucleico, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica e usos do anticorpo
BR112014002140A2 (pt) anticorpo anti-cxcr4 e uso do mesmo para a detecção e o diagnóstico de câncer
BR112016007479A2 (pt) regimes de dosagem de imunoconjugado de anti-folr1
BR112014013876A2 (pt) vacina à base de toxina de clostridium difficile
BR112015010220A2 (pt) métodos de utilização de biomarcadores para tratamento de câncer
BR112012022243A8 (pt) Uso de um inibidor de autofagia baseado em tioxantona e de um composto indutor de autofagia para terapia de câncer, composição farmacêutica e kit farmacêutico
BR112017025533A2 (pt) método para tratar câncer em um paciente humano
BR112012014159A2 (pt) Combinações terapêuticas de teobromina e um anti-histamínico
BR112014032916A2 (pt) anticorpos anti-fármacos e usos destes para o monitoramento de fármaco

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2560 DE 28/01/2020.